January 24, 1993 |
It was boom times last year for Lemmon Co. And the Sellersville generic-drug maker has U.S. patent laws to thank. The company launched seven new medicines in 1992 - more than ever before. But each was a copy of a drug that had been made only as a brand-name drug - that is, until their patents expired recently. So successful were Lemmon's new products that the company's sales grew by 40 percent last year, transforming the 46-year-old company into a major generic-drug maker, with annual sales of $100 million.
October 30, 2001
I'M AN admirer of Michelle Malkin, but I'm disturbed by her drug industry column of Oct. 18. First I would ask, how many shares of drug industry stock does she have in her portfolio. Second, how can an industry that makes multi-billions in profits, spend hundreds of million in advertising, another hundreds of million buying off generic drug makers and pay in the hundreds of million for campaign financing then cry poor mouth when questioned about the cost of their drugs to the working class and poor of this nation?
September 22, 2012 |
A $300 million program to speed U.S. reviews of generic drugs made by Mylan Inc., Teva Pharmaceutical Industries Ltd. and other companies may not start as planned on Oct. 1 because of a budget impasse in Congress. The industry's deal with the Food and Drug Administration to pay user fees for the first time was to mimic long-standing arrangements for brand-name drugs and medical devices. The snag for generics is that because their program is new, lawmakers must pass legislation authorizing the FDA to collect the money, Donald Beers, associate chief counsel for drugs at the agency, said at a meeting in Silver Spring, Md. Friday.
December 6, 1989 |
After only a few minutes of listening to Dr. Emerita T. Gueson, the 20 Natural Food Association members prepared to wage a battle against the multimillion-dollar generic-drug industry. As Gueson spoke Thursday about the hazards of generic drugs, Felicia Schnipper, executive director of the association, prepared a petition calling for better industry controls. "Generic drugs are not the same as brand-name drugs," said Gueson, an outspoken physician with obstetrics/gynecology practices at Nazareth Hospital in the Northeast and Holy Redeemer Hospital in Montgomery County.
January 17, 1991 |
Saying that "the generic-drug scandal is not abating," Rep. John D. Dingell (D., Mich.) yesterday criticized the Food and Drug Administration after two makers of generic drugs admitted further improprieties. Pharmaceutical Basic Inc., of Denver, and Duramed Pharmaceuticals, of Cincinnati, said they were withdrawing more of their products from the market. Pharmaceutical Basic was barred from doing business with the Defense Department during 1990 because of a bribery scandal and was reinstated to the government contractors' list only two weeks ago. It said it was halting distribution of all its products after discovering new evidence of falsifications by its employees in documents being submitted to the FDA. In 1989 and last year, two Pharmaceutical Basic officials pleaded guilty to bribing FDA employees in an attempt to gain rapid approvals of generic drugs.
August 27, 1989 |
Soon after one competitor conceded it had cheated in testing its generic version of SmithKline Beecham's Dyazide and the same day similar concerns were raised about another rival, SmithKline lashed out. "This news certainly reaffirms the necessity for dispensing your Dyazide prescriptions with the branded product," SmithKline wrote pharmacists amid the revelations that its high-blood-pressure medication had been substituted for the generic version...
September 12, 1989 |
The troubles hounding the generic-drug industry deepened yesterday when Food and Drug Administration inspectors told a congressional subcommittee that they had found a multitude of manufacturing problems in 11 of 13 firms under investigation. The problems outlined to the House Energy and Commerce investigations subcommittee included sloppy record-keeping, inconsistent test data, poor production practices and falsified information submitted to the FDA. The violations varied among the 11 firms.
March 7, 2013 |
Generic drugs have dramatically changed the pharmaceutical and health-care landscape in the last 25 years and now account for about 80 percent of prescriptions in the United States, with lower prices for consumers and insurers. But a U.S. Supreme Court case scheduled for argument March 25 pits drug companies, generic and branded, against government officials who argue that prices for consumers would be even lower if those companies did not strike deals to restrain trade. Drugstore chains and health insurers back the government's side.
May 25, 2012 |
Teva Pharmaceuticals Ltd.'s new chief executive officer, Jeremy Levin, said Thursday that he has changed the leadership lineup in hopes of regaining more of the U.S. generic drug market, in which Teva has dominated for years but now faces increasing competition. Chief financial officer Eyal Deshah said the company has "instituted a cost-cutting and efficiency program throughout Teva's operations," but a spokeswoman later said via e-mail that there have been no new layoffs, including in the Americas division, which encompasses facilities in the Philadelphia area.
December 20, 1990 |
Serious problems of fraud and other misconduct remain in the generic-drug industry despite a two-year federal investigation, officials said yesterday. Generic drugs are lower-cost substitutes for brand-name prescription drugs. Federal regulations require that generics be equivalent to the higher-priced brand names, both in terms of their effectiveness in treating illnesses and their shelf life. Many doctors routinely prescribe generics to help patients save money. Federal authorities, in their investigation, found that some generic-drug officials were bribing Food and Drug Administration officers to speed approval of inadequately tested products.